Amarin Q2 2025 Earnings Preview
Source: SeekingAlpha
2025-07-29 10:56:01 ET
More on Amarin
- Amarin Is A Sell Despite The Large Cash Balance
- Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript
- Amarin Corporation plc 2025 Q1 - Results - Earnings Call Presentation
- Amarin inks licensing deal with Recordati for lead drug Vazkepa
- Seeking Alpha’s Quant Rating on Amarin
Read the full article on Seeking Alpha
For further details see:
Amarin Q2 2025 Earnings Preview
Amarin Corporation plc
NASDAQ: AMRN
AMRN Trading
-4.29% G/L:
$15.60 Last:
33,812 Volume:
$16.39 Open:
AMRN Latest News
March 07, 2026 01:35:00 am
Here's Why I Wouldn't Touch Amarin With a 10?Foot Pole Given Its Patent and Competition Risks
AMRN Stock Data
$312,618,004
18,426,477
1.2%
30
N/A
Pharmaceuticals
Healthcare
IE
Dublin 2
